Efficacy of neoadjuvant chemoradiotherapy with 5-fluorouracil/cisplatin versus paclitaxel/cisplatin in esophageal squamous cell carcinoma: A single-institute real-world study

The study findings suggest that both 5-fluorouracil/cisplatin and paclitaxel/cisplatin regimens demonstrate comparable efficacy and safety profiles as neoadjuvant chemotherapy options for locally advanced ESCC. Decisions regarding the choice of regimen should consider factors such as treatment accessibility, financial costs, and patient preferences. Further research, including randomized controlled trials, is warranted to validate these findings and guide clinical decision-making effectively.